The osteoclast plays an important role in bone resorption in vertebrates during development and throughout life (1) . This resorption is counterbalanced by new bone formation from osteoblasts. This process of coupling the actions of the boneproducing cells, the osteoblasts, and the bone-resorbing cells, the osteoclasts, is termed "bone remodeling," a process necessary for maintaining a constant bone mass throughout the lifetime of vertebrate organisms. Disruption of this process in humans results in diseases of bone, including osteoporosis and hypercalcemia of malignancy (2, 3) .
Osteoclasts differentiate from cells of the monocyte/macrophage lineage to become multinuclear, tartrate-resistant acid phosphatase (TRAP) 1 -positive cells capable of resorbing bone (4) . Osteoclast differentiation is influenced by hormones and local factors produced by the osteoblasts and stromal cells (4) . One local factor expressed by osteoblasts is receptor activator of NF-B ligand (RANKL) (5) (6) (7) (8) (9) (10) . RANKL is a member of the tumor necrosis factor superfamily that is important for maturation of T-and B-cells as well as osteoclasts (7) . Mice containing a targeted deletion in either the RANK receptor or RANKL lack differentiated osteoclasts and develop severe osteopetrosis (7) (8) (9) .
RANKL/RANK signal through tumor necrosis factor receptor-associated factors to activate multiple signaling pathways thought to be important for osteoclast differentiation and function, including NF-B, mitogen-activated protein kinase (MAPK) pathways, Src kinase, and phosphatidylinositol 3-kinase pathways (11, 12) . Recently, it has been shown that inhibition of the p38 signaling pathway in bone marrow-derived osteoclast precursor cells by treatment with the drug SB203580 inhibited the formation of multinuclear, functional osteoclasts that expressed TRAP in response to RANKL treatment (13) . In contrast, the drug PD98059, a specific inhibitor of the MAPK p42/44 pathway, had no effect on the differentiation of bone marrow cells. These results indicate that the p38 MAPK signaling pathway is involved in RANKL-induced differentiation of bone marrow-derived precursor cells (13) .
The microphthalmia-associated transcription factor (MITF) is a basic helix-loop-helix leucine zipper protein (14, 15) closely related to the transcription factors TFE3, TFEB, and TFEC (16 -18) . MITF regulates osteoclast target genes like TRAP, cathepsin K, and E-cadherin by binding to a 7-base pair conserved sequence TCANGTG found in the promoter regions of these genes (19 -21) . In situ hybridization experiments confirmed that MITF is expressed in osteoclasts beginning at the earliest stages of endochondral ossification of long bones (19) . A mutant allele of the MITF gene, mi, encodes a protein product lacking one of four arginines in the basic region of the MITF protein critical for binding to target genes (14, 22) . Osteoclastlike precursor cells derived from mice homozygous for the mi mutation are incapable of fusing to form multinuclear cells, lack a ruffled border, express low levels of TRAP and cathepsin K, and cannot efficiently resorb bone (19, 21, 23, 24) . Based on the similarity of the phenotype of the bone marrow-derived precursor cells blocked for p38 MAPK activity and the mi/mi osteoclasts-like cells, we hypothesized that MITF may be a target of the p38 MAPK in osteoclasts.
In this study, we investigate whether MITF is a potential target of the p38 MAPK in osteoclasts. We show that MITF was persistently phosphorylated on a conserved serine 307 in primary osteoclast-like cells in response to RANKL signaling and that phosphorylation of serine 307 correlated with expression of the target gene, TRAP. Further, p38 MAPK could phosphorylate serine 307 in vitro, and phosphorylation of MITF at serine 307 increased the ability of the factor to stimulate the TRAP promoter activity in transient transfection assays. We conclude that MITF may be a direct target of a RANKL/p38 signaling pathway that is necessary for osteoclast differentiation and function.
EXPERIMENTAL PROCEDURES
Culture and Analysis of OCLs-Hematopoietic precursors were obtained from the bone marrow of wild type mice. OCLs were grown in the presence of 50 ng/ml colony-stimulating factor-1 (CSF-1) for 3 days. CSF-1 was lowered to 5 ng/ml, and then RANKL was added at 100 ng/ml for the indicated times. SB203580 (Calbiochem) was used at the indicated concentration, 10 M, and was applied to the cells 30 min before stimulation with RANKL.
DNA Constructs and Transfections-For all experiments presented here, the melanocyte form of the MITF cDNA was used (14, 25) . The MITF phosphorylation mutant, termed S307A/P308A, was made by replacing conserved serine and proline with alanine residues. The point mutant was verified by sequencing. The full-length form or point mutants were cloned into a vector providing the influenza hemagglutinin tag (HA) (Roche Molecular Biochemicals). Wild type TRAP promoter and the TRAP promoter containing the E box mutation were previously described (19) .
Bacterial expression constructs of His-tagged MKK6b(E) and p38␣ (26) , dominant negative expression plasmids for p38 ␣, ␤, ␥, and ␦ isoforms (27) , and MKK6(E) expression plasmid were all previously described (28) .
DNA transfections of RAW 264 cells have been previously described (19) .
Construction of Cell Lines-RAW 264.7 cells were transfected with Superfect (Qiagen) following the manufacturer's directions with either the plasmid expressing HA-tagged S73AMITF or HA-tagged S73A/ S307A/P308AMITF, and cells were selected using 100 g/ml Geneticin (Invitrogen). Individual clones were picked and screened for expression of HA-MITF.
Preparation of Recombinant Proteins-Recombinant p38 isoforms and MKK6(E) were prepared by a previously described method (27) . MITF corresponding to amino acids 297-377 (nucleotides 1018 -1263) was cloned into pGEX2t (Pharmacia) and was purified to 95% purity by glutathione Sepharose affinity chromatography. Versions of the protein with either serine or alanine at amino acid position 307 were produced and purified.
RANKL Bacterial Expression and Purification-RANKL corresponding to amino acids 158 -316 (nucleotides 472-978) was placed into vector pET 32b (Novagene), purified by native lysis to 95% purity by nickel-Sepharose (Qiagen) affinity chromatography and eluted in imidazole. The concentration of soluble RANKL was optimized for induction of p38 phosphorylation and formation of TRAP-positive osteoclasts with each preparation.
Immunological Reagents and Analysis-The peptide PSTGLSpSP-DLVN (where pS represents phosphoserine), corresponding to amino acids 301-312 of MITF was synthesized (QCB/BIOSOURCE, Hopkinton, MA). The position of the phosphate at amino acid 307 was confirmed by NMR. The phosphopeptide was used to immunize two New Zealand White rabbits. Collected serum was pooled and passed over a column to which the nonphosphopeptide was coupled, and material that did not bind to this column was collected and passed over a phosphopeptide affinity column. Bound material was eluted from this second column with glycine buffer, dialyzed against phosphate-buffered saline, and stored at Ϫ70°C. Polyclonal phosphorylation-independent MITF antibody has been described previously (20) . p38 ␣-and ␤-specific antibodies were previously described (26) . Antibodies that recognized p38 MAPK were obtained from New England Biolabs Cell Signaling.
Western blotting was performed with nitrocellulose membranes and the ECL detection system (Kirkegaard and Perry Laboratories). For Western blots using the antibodies that recognize total or phosphorylated p38, the manufacturer's protocol was followed. For the phosphospecific MITF antibody, the blot was blocked in TBS (50 mM Tris, pH 7.5, 150 mM NaCl), 0.1% Tween 20, 5% powdered milk for 2 h at room temperature. The blot was washed three times in TBS, 0.1% Tween 20. The phosphospecific MITF antibody was added to fresh blocking buffer and incubated for 2 h at room temperature. S]methionine (ICN) was added to the cells, and the cells were labeled for 3 h. Cells were lysed in RIPA (50 mM Tris-HCl, pH 7.6, 125 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate) that included 10 g/ml antipain, 10 g/ml leupeptin, 10 g/ml aprotinin, and 1 mM sodium vanadate. Cells were incubated in RIPA at 4°C for 20 min and then centrifuged at 25,000 rpm for 20 min. Protein G beads (Amersham Biosciences) were added to the lysate, and the antibody (HA from Babco) was added. The immunoprecipitates were incubated overnight at 4°C. The immunoprecipitates were washed three times in RIPA and run on an 8% SDS-PAGE.
Kinase Assay-Full activation of recombinant p38 ␣ in vitro was achieved by incubation with recombinant MKK6(E) at a 5:1 molar ratio at 37°C for 15 min in the presence of ATP as previously described (27) . In vitro kinase assays were carried out at 37°C for 15 min, using 0.2 g of recombinant kinase, 5 g of GST-MITF, 250 M ATP, and 12 Ci of [␥-
32 P]ATP in 20 l of kinase reaction buffer. Reactions were terminated by the addition of SDS sample buffer. Reaction products were resolved on a 10% SDS-PAGE. Phosphorylated proteins were visualized by autoradiography.
p38 MAPK activities were measured in an immune complex kinase assay. RAW264.7 cells were stimulated with RANKL at 100 ng/ml for 15 min. Cells were lysed in RIPA. Cells were incubated in RIPA at 4°C for 20 min and then centrifuged at 25,000 rpm for 20 min. The immunoprecipitates were incubated with anti-p38 antibody (Cell Signaling Technology) overnight at 4°C. The immunoprecipitates were collected and washed three times in RIPA and two times with kinase buffer (20 mM Mops, pH 7.5, 25 mM ␤-glycerol phosphate, 10 mM MgCl 2 , 1 mM dithiothreitol, 1 mM sodium vanadate). Immunoprecipitates of anti-p38 were mixed with 0.5 g of GST-MITF, 150 M ATP, and 12 Ci of [␥-
32 P]ATP in 50 l of kinase buffer. The reactions were further incubated at 30°C for 30 min. Reactions were terminated by the addition of SDS sample buffer. Reaction products were resolved on a 10% SDS-PAGE. Phosphorylated proteins were visualized by autoradiography.
RESULTS

Production and Characterization of Antibodies Specific for
MITF Phosphoserine 307-Osteoclasts that are grown in the presence of CSF-1 and RANK ligand but have been blocked for the activation of the p38 MAPK by the specific inhibitor SB203580 remain mononuclear and stain weakly for the osteoclast marker TRAP (13), a similar phenotype to the osteoclasts that are cultured from the mice homozygous for the mi mutation (23, 24) . This led us to test the hypothesis that MITF might be a target of the p38 MAPK pathway during osteoclast differentiation. We analyzed the amino acid sequence of MITF and discovered a potential p38 phosphorylation site at serine 307 that is conserved among different species including human, mouse, and chicken (Fig. 1A) . However, the serine at amino acid position 307 is not conserved among the other related transcription factors, TFEC, TFE3, and TFEB (29) .
To begin to investigate if MITF was phosphorylated at serine 307 in osteoclasts, an antibody that was specific for the phosphorylated serine at residue 307 was developed (see "Experimental Procedures"). For this purpose, the peptide PSTGLSp-SPDLVN (corresponding to amino acids 301-312 of MITF) was synthesized and used to produce polyclonal rabbit serum. Following affinity purification, the specificity of the antibody for detecting phosphoserine 307 MITF in Western blotting experiments was tested with recombinant GST-MITF corresponding to amino acids 297-377. For these experiments, the GST-MITF region was incubated in vitro with activated p38 ␣ and ATP (Fig. 1B) . These experiments showed that only GST-MITF that had been incubated with the p38 preparation was recognized by the antibody (Fig. 1B, lane 1 versus lane 2) . Recombinant protein containing alanine substituted for serine at amino acid position 307 was not recognized by the phosphospecific antibody in either the presence or absence of activated p38 MAPK. (Fig. 1B, compare lanes 3 and 4 with lane 1) . When the blot in Fig. 1B was stripped and reprobed with an antibody specific for the GST moiety, we were able to detect the recombinant protein in all four lanes (Fig. 1B, bottom panel) .
To further characterize the phospho-Ser 307 -specific antibody, RAW 264.7 cell lines that stably expressed either HA-tagged MITF or S307A/P308A HA-tagged MITF were created. The cells were stimulated with RANKL for various times, and cell extracts were prepared and immunoprecipitated with the antibody recognizing the HA epitope. The phosphorylation status of MITF Ser 307 was determined using the phosphospecific MITF antibody (Fig. 1C, top panel) . This analysis demonstrated that Ser 307 was phosphorylated following 15, 30, or 60 min with RANKL stimulation but that the antibody did not react with the S307A/P308A MITF protein. The bottom panel of MITF Is Rapidly and Persistently Phosphorylated in Osteoclasts after RANKL Stimulation-The anti-phospho-MITF antibody was used to determine the phosphorylation status of endogenous MITF in primary osteoclast precursors after stimulation by RANKL. Bone marrow-derived osteoclast precursors were obtained from wild type mice and cultured in the presence of CSF-1 for 3 days. At this time, RANKL was added to the bone marrow cell cultures, and nuclear extracts were prepared and analyzed by Western blotting (Fig. 2) . Using the anti-phosphoSer 307 antibody, MITF phosphorylation could be detected following 30 min of RANKL stimulation and persisted following 24 h of continuous RANKL treatment ( Fig. 2A, upper panel) . When the same blot was reprobed with a nondiscriminating MITF antibody, approximately equal levels of MITF protein are seen in all lanes ( Fig. 2A, lower panel) . MITF appeared as a doublet with electrophoretic mobility of around 55 and 57 kDa in these experiments, and both bands are detected by the anti-phospho-Ser 307 antibody ( Fig. 2A) . Previous work in melanocytes has also indicated that MITF is resolved as a doublet in extracts prepared from this cell type and that the upper band is due to c-Kit-mediated phosphorylation of conserved serine residue 73 (30) . Ser 73 is also phosphorylated in osteoclasts in response to CSF-1, accounting for the doublet band pattern in this cell line as well (31) . As shown below (see Fig. 5 ) mutation of Ser 73 to alanine results in a loss of the slower migrating band (see Fig. 5 ).
Real time PCR was used to measure expression of the MITF target gene TRAP (19) following RANKL stimulation of osteoclasts (Fig. 2B) . These experiments demonstrated that TRAP expression was increased ϳ7-fold following 30 min of RANKL treatment and remained elevated 7-fold, following 24 h of Both TRAP and glyceraldehyde-3-phosphate dehydrogenase RNA were quantitated. All values in the chart are expressed as the ratio of TRAP to glyceraldehyde-3-phosphate dehydrogenase expression and then further normalized to the CSF-1-only control. C, p38 MAPK is phosphorylated in response to RANKL stimulation in osteoclasts. The top panel is a Western blot of whole cell extracts from osteoclasts, run on a 10% SDS-PAGE and probed using phosphospecific p38 antibody. The numbers above the lanes indicate the hours after RANKL stimulation that the extracts were collected. The bottom panel is the same blot in the top panel reprobed with an antibody that recognizes all forms of p38 MAPK.
RANKL treatment, in good agreement with the observed increase in MITF Ser 307 phosphorylation. As previously reported in RAW 264.7 cells (13), we were able to detect the phosphorylated, activated form of p38 MAPK in primary osteoclasts following stimulation with RANKL (Fig.  2C) . The phosphorylation of p38 MAPK, like the phosphorylation of MITF, was persistent, since we were able to detect phosphorylated p38 MAPK even 24 h after stimulation with RANKL (Fig. 2C, top panel) . This blot was stripped and reprobed with an antibody that recognizes all forms of p38 to ensure that there was approximately equal loading of protein in all lanes (Fig. 2C, bottom panel) . This second antibody detected the same 42-kDa protein in all samples, even the sample that received only CSF-1.
The effects of the specific p38 MAPK inhibitor, SB203580, on MITF Ser 307 phosphorylation and TRAP gene expression were examined (Fig. 2, A and B) . This analysis demonstrated that MITF Ser 307 phosphorylation in response to RANKL could be inhibited by SB203580 pretreatment of osteoclasts (Fig. 2A,  lane 3) . Additionally, TRAP gene induction by RANKL could be reduced from 7-to 3-fold by SB203580 pretreatment (Fig. 2B) .
p38 Can Phosphorylate MITF in Vitro-To provide additional evidence linking MITF phosphorylation to p38 MAPK, in vitro kinase reactions were performed. Two types of assays were used. First, p38 MAPK immunoprecipitated from RAW264.7 was used in immune kinase reactions with GST-MITF substrate (Fig. 3A) . The immune kinase experiments demonstrated that the p38 immunoprecipitate prepared from RANKL-treated cells phosphorylated the GST-MITF protein, whereas one prepared from unstimulated cells did not (Fig. 3A,  compare lane 1 and lane 3) . Additionally, an MITF protein containing S307A/P308A mutations was a poor substrate in the assay, whether p38 was immunoprecipitated from RANKLtreated or -untreated cells (Fig. 3A, lanes 2 and 4) .
In the second assay, the ability of recombinant p38␣ to phosphorylate GST-MITF was tested. Recombinant p38␣, activated in vitro by constitutively active MKK6 (28), could phosphorylate wild type GST-MITF (Fig. 3B, lane 1) . The level of phosphorylation of the Ser 307 protein was ϳ5-fold higher than phosphorylation of S307A-mutated MITF protein (Fig. 3B, compare  lanes 1 and 3) . The phosphorylation of GST-MITF depended on the addition of both MKK6 and p38␣ (Fig. 2C, lanes 2 and 4) , and GST alone was not phosphorylated by either kinase (Fig.  2C, lanes 5 and 6) . In similar experiments, the p38 ␤ isoform could also phosphorylate GST-MITF, but the p38 ␥ isoform could not (data not shown).
c-Jun N-terminal kinase MAP kinase could not phosphorylate GST-MITF substrates in vitro in either type of assay, under conditions where a GST-Jun substrate could be phosphorylated (data not shown).
Dominant Active Forms of Rac1 and MKK6 Can Collaborate with MITF to Superactivate the TRAP Promoter in Transient
Assays-Rac1 and has been previously shown to be able to activate the p38 MAPK cascade (28) . Further, MKK6 has been previously shown to be a MAPK kinase that is a specific activator of p38 MAPKs (28, 32) . To provide additional evidence documenting MITF as a downstream target of the RANKL/p38 MAPK signaling pathway, we tested whether MITF's ability to transactivate the TRAP promoter fused to a firefly luciferase reporter gene was stimulated by Rac1(15L) or MKK6(E), constitutive active forms of these molecules. Experiments were performed in the macrophage/osteoclast cell line RAW 264.7 (Fig. 4) .
In these experiments, co-transfection of the TRAP reporter with MITF expression vector resulted in approximately a 10-fold increase in promoter activity compared with control basal activity in agreement with our previously published results (19) (Fig. 4) . When either Rac1(15L) or MMK6(E) expression vectors were co-transfected with the TRAP reporter, there was an ϳ4 -5-fold increase in TRAP promoter activity compared with basal activity (Fig. 4) . When the combination of Rac1(15L) and MITF expression vectors was co-transfected with the TRAP promoter, there was a more than 100-fold increase in promoter activity relative to the control (Fig. 4 , compare bar 1 with bar 5), an effect that was more than additive of the effects seen with MITF or Rac1(15L) expression vectors alone. When a TRAP reporter that contains point mutations in the E boxrelated MITF-binding site identified in our previous studies (19) was tested in combination with MITF and Rac1(15L), activation was abolished (Fig. 4, compare bar 5 with bar 6) .
Co-transfection of MITF and MKK6(E) with either TRAP reporter produced similar results, a 100-fold activation of wild type reporter and no activation of the MITF-binding site mu- tation (Fig. 4 , compare bar 5 with bar 6 and compare bar 7 with bar 8, respectively). These experiments indicate that MITF collaborates with the Rac/MKK6 signaling pathway to stimulate TRAP promoter activity dependent on the cis-acting MITFbinding site present in the TRAP promoter.
Serine 307 and Proline 308 Are Necessary for MITF Collaboration with Rac1 and MKK6 -As discussed above, serine 307 is phosphorylated in vivo in response to RANKL signaling and is a substrate for p38 MAPK in vitro. To test the role of this phosphorylation site in MITF collaboration with either Rac1(15L) or MKK6(E), the HA-MITF protein containing S307A/P308A (see Fig. 1 ) was studied in the transient transfection assays in RAW264.7 cells (Fig. 5A) . When co-transfected with the TRAP reporter, the MITF S307A/P308A expression vector was able to transactivate the TRAP promoter to similar levels as observed with the wild type MITF gene (Fig. 5A) . In contrast, MITF S307A/P308A co-transfected with constitutively active Rac1 or MKK6 could not activate the TRAP promoter to the same levels as wild type MITF (Fig. 5A) . Mutation of other potential serine phosphorylation sites (e.g. an S73A point mutation in the previously characterized Erk phosphorylation site (30, 31)) had no affect on stimulation of MITF activity by either Rac1(15L) or MKK6(E) (data not shown).
To determine whether the alanine substitutions affected protein stability, we examined expression of HA-tagged MITF proteins following transfection of COS cells (Fig. 5B) . In these experiments, both MITF wild type and S307A/P308A forms were again resolved as doublets. However, MITF with the S73A substitution ran as a single, faster migrating band, consistent with the previous finding that phosphorylation of this site by the Erk MAPK pathway results in the band with lower electrophoretic mobility (30, 31) . No significant difference in the levels of the wild type MITF or MITF S307A/P308A proteins could be detected in this assay (Fig. 5B) . Taken with the data above showing that S307A/P308A MITF can be stably expressed to the same extent as wild type protein in RAW264.7 cells (Fig. 1C, bottom panel) , these results indicate that MITF protein stability is not grossly affected by these point mutations.
p38 ␣ and ␤ Dominant Negative Can Inhibit Rac1/MITF Activation-There are four p38 isoforms (␣, ␤, ␥, and ␦), encoded by separate genes (26, (33) (34) (35) . We were interested in determining which isoform(s) of p38 was involved in osteoclastogenesis. Since SB203580 has been shown to inhibit only p38 ␣ and ␤ isoforms at low doses used in the experiments presented above (36) , it was likely that one or both of these isoforms were involved in osteoclast differentiation. Western analysis was performed with p38 antibodies specific for the p38 ␣ or ␤ isoforms (26) . The p38 ␣ isoform was detected in both RAW 264.7 and OCL whole cell extracts (Fig. 6A, lanes 1 and 2) . However, we were unable to detect expression of p38 ␤ in either RAW 264.7 or OCLs, although the antibody did recognize recombinant p38 ␤ protein included on the blot as a positive control (Fig. 6A, compare lanes 5, 6, and 7, respectively) .
To test if dominant negative versions of the four isoforms of p38 (27) could inhibit Rac1 activation of MITF, transient transfections were performed with RAW 264.7 cells (Fig. 6B) . As shown above, co-transfection of MITF and Rac1 (15L) expression vectors with the TRAP reporter resulted in 100-fold activation of the TRAP promoter relative to the control (Fig. 6B , compare bar 1 with bar 4). When dominant negative expression vectors for p38 ␥ and ␦ were co-transfected with MITF and Rac1 expression vectors, we detected no significant decrease in luciferase activity compared with when MITF and Rac1 expression vectors were co-transfected together (Fig. 6B, right panel) . However, when expression vectors for the isoforms p38 ␣ and ␤ were co-transfected with MITF and Rac1 expression vectors, the luciferase activity of the TRAP promoter was similar to levels seen when only MITF or Rac1 was co-transfected with the TRAP-luciferase reporter (Fig. 6B , left panel, compare bar 4 with either bar 5 or bar 6, respectively). Although our analysis indicated the p38 ␤ isoform was not expressed in primary osteoclast-like cells, the fact that the dominant-negative version of the gene could still interfere with Rac1 activation of MITF is not surprising, given the high level of similarity between the p38 ␣ and ␤ isoforms.
DISCUSSION
In this study, we present evidence indicating that MITF is a direct target of a RANKL/p38 signaling pathway and that activation of MITF by this pathway is necessary for efficient expression of TRAP. MITF is thus defined as a nuclear target for RANKL signaling that, along with p38 MAPK activity, is persistently, and not transiently, activated by RANKL. Studies on other signaling pathways activated by RANKL, specifically the IB/NF-B and c-Jun N-terminal kinase/c-Jun pathways, have not addressed the issue of persistence but have only studied activation within 30 min of RANKL treatment (10, 37, 38) . RANKL can stimulate transient, acute inflammatory responses as well as promoting osteoclast differentiation (7). Thus, defining whether signaling pathways are activated in a transient or persistent manner is probably critical for understanding how RANKL promotes inflammatory responses as opposed to differentiation.
The p38 kinases constitute a distinct MAPK subfamily that plays a role in adaption, homeostasis, and stress responses (39) . In addition, the p38 pathway has been implicated in the induction of myoblast differentiation (40, 41) . There are interesting parallels between the role of p38 in muscle differentiation and in osteoclast differentiation. The myogenic MEF transcription factors are targets of p38 signaling (27, 42) . Additionally, the p38 MAPK pathway is persistently activated and maintained during the whole process of myotube formation (41) . As is the case for the p42/p44 MAPK kinase in neuronal cell differentiation (43) , persistent activation of signaling appears necessary for the ability of the p38 MAPK pathway to promote cell differentiation in myoblasts and osteoclast precursors. In muscle differentiation, the identity of the factor that triggers p38 activation is unknown (41), unlike osteoclast differentiation, where RANKL is the factor that stimulates differentiation. The RANKL/p38 MAPK/MITF pathway provides a paradigm to define how persistent activation of signaling occurs.
MITF regulates distinct sets of target genes in different cell types, and a major question is what mechanisms allow for cell type-specific actions of MITF. The results presented here suggest that cell type-specific signaling events may contribute to the ability of MITF to selectively alter the expression of target genes in one cell type versus another. For example, the expression of RANK in osteoclast precursors distinguishes this cell type from melanocytes and thus allows for cell type-specific phosphorylation and activation of MITF. Importantly, the conserved Ser 307 residue is not conserved among the related family members TFE3, TFEC, and TFEB (29) . This is distinct from the conserved Ser 73 residue, a target for the Raf/p42/p44 MAPK pathway (30, 31) , a site conserved among the entire family (29) . Thus, MITF may be regulated by the p42/p44 MAPK pathway in all cell types in which it is expressed, but phosphorylation of serine 307 may represent one mechanism of regulating MITF activity that is unique to osteoclasts.
How does phosphorylation at Ser 307 modulate MITF activity in osteoclasts? Recent results suggest that two probable mechanisms should be considered. First, our laboratory has recently demonstrated that MITF and the Ets family member PU.1 interact uniquely in osteoclasts to regulate target genes and to promote osteoclast differentiation (44) . One hypothesis is that phosphorylation of MITF by the p38 MAPK pathway increases the affinity of the interaction between MITF and PU.1 and thus increases the ability of this pair of transcription factors to stimulate osteoclast differentiation. A second hypothesis is that phosphorylation of MITF lowers its affinity for a co-repressor.
For example, in muscle differentiation, calcium/calmodulin signaling leads to a dissolution of a complex between MEF2 proteins and histone deacetylases and allows MEF2 to interact with the helix-loop-helix factor MyoD to trigger muscle differentiation (45) . The two hypotheses are not mutually exclusive. It could be that phosphorylation of MITF on serine 307 leads to a lower affinity for a co-repressor and subsequent high affinity interaction with PU.1. Further analysis will be required to determine whether these hypotheses can account for the ability of p38 MAPK to activate MITF.
The work presented here indicates that osteoclast-specific signaling events may contribute to the ability of MITF to regulate osteoclast gene expression and differentiation. These results suggest a unique set of molecular targets that might allow modulation of osteoclast differentiation and activity in bone disorders caused by the uncoupling of osteoblast and osteoclast action (e.g. osteoporosis).
